CN Patent

CN117164580A — 一种kras g12c抑制剂的制备方法及其中间体

Assigned to Suzhou Zelgen Biopharmaceutical Co Ltd · Expires 2023-12-05 · 2y expired

What this patent protects

本发明公开了一种KRAS G12C抑制剂的制备方法及其中间体。本发明方法工艺路线简洁、高效、低成本、低污染、安全性高、无柱层析纯化操作，制备的目标产物HPLC纯度大于99.0％，产物的ee值大于99.0％。因此，本发明制备方法更适合工业化应用。

USPTO Abstract

本发明公开了一种KRAS G12C抑制剂的制备方法及其中间体。本发明方法工艺路线简洁、高效、低成本、低污染、安全性高、无柱层析纯化操作，制备的目标产物HPLC纯度大于99.0％，产物的ee值大于99.0％。因此，本发明制备方法更适合工业化应用。

Drugs covered by this patent

Patent Metadata

Patent number
CN117164580A
Jurisdiction
CN
Classification
—
Expires
2023-12-05
Drug substance claim
No
Drug product claim
No
Assignee
Suzhou Zelgen Biopharmaceutical Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.